SH
Sanjay Harakchand Gugle
About Sanjay Harakchand Gugle
Sanjay Harakchand Gugle has 24 years in corporate governance. Holds Director role. Currently with 2 companies, including Trans Pharmaceuticals Private Limited and Zenesis Remedies Private Limited. Formerly with 2 companies, such as Huge Suntech Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Trans Pharmaceuticals Private Limited
U24112PN2010PTC136897
|
Director | 20 Jul 2010 | 2010 | Active |
H.U.Gugle Biotech Private Limited
U73100KA2003PTC032149
|
Director | 30 Nov 2016 | 2003 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Huge Suntech Private Limited
U35105PN2016PTC158210
|
Director | 03 Feb 2016 | 2016 | Active |
Zenesis Remedies Private Limited
U24231PN2002PTC017037
|
Director | 05 Jun 2002 | 2002 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Sanjay Harakchand Gugle
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sanjay Harakchand Gugle
Sanjay Harakchand Gugle has 24 years in corporate governance. Holds Director role. Currently with 2 companies, including Trans Pharmaceuticals Private Limited and Zenesis Remedies Private Limited. Formerly with 2 companies, such as Huge Suntech Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Sanjay Harakchand Gugle is associated with 2 companies as Director.
Sanjay Harakchand Gugle has expertise in General Business, Technology.
Sanjay Harakchand Gugle has 24 years in corporate governance.